Clinical Trial Update: Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of volociximab and erlotinib in patients with stage III or stage IV non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Volociximab (volociximab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN